查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529671

甲癬市場規模、佔有率、趨勢分析報告：按類型、治療、區域、細分市場預測，2024-2030

Onychomycosis Market Size, Share & Trends Analysis Report By Type (Distal Subungual, White Superficial, Proximal Subungual Onychomycosis), By Treatment (Oral, Topical), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 140 Pages | 商品交期: 2-10個工作天內

價格

甲癬市場成長與趨勢：

根據Grand View Research, Inc.的最新報告，預計2030年全球甲癬市場規模為49.4億美元，預計2024年至2030年複合年成長率為4.4%。

甲癬市場的成長歸因於甲癬和慢性疾病發病率的增加以及治療意識的提高。感染疾病會導致心理和社會限制，限制工作和社交生活，因此，為患有感染疾病的患者提供有效且高效的治療變得重要，進一步推動市場成長。

甲癬的成長是推動整體市場成長的主要因素。這種感染疾病通常稱為甲癬或指甲真菌感染疾病，影響著美國14% 以上的人口。然而，儘管甲癬具有高度傳染性，並且患甲癬的風險隨著老齡化的成長而增加，但大多數人並沒有意識到甲癬的危害有多大。

全球灰指甲組織等國際組織與世界各地的公共衛生相關人員和醫療保健專業人員合作，提高對灰指甲的認知並改善世界各地的預防和治療。預計這將推動對治療藥物的需求。美國疾病管制與預防中心 (CDC) 的 Think Fungus 等政府舉措有助於在患者病程早期識別甲癬等真菌疾病，並確保採取適當的治療措施。因此，對甲癬治療的需求正在迅速增加，預計將推動該國市場的成長。

此外，主要參與者正專注於合作研究和合作夥伴關係，以開發新型甲癬治療方法並保持市場競爭力。例如，2022年8月，Moberg Pharma AB預計將與Padagis Israel Agencies Ltd.簽訂經銷協議，授予Padagis治療趾甲足癬藥物MOB-015在以色列的獨家經銷權。此外，解決諸如提高患者依從性和減少劑量等問題的技術創新預計將推動市場成長。例如，Intas Pharmaceuticals於2021年10月推出了SB 100mg，這是世界上第一個超級生物利用度的Itraconazole，商品名為Itaspor-SB Forte/Subawin。這項措施預計將顯著提高患者的依從性並降低治療成本。

甲癬市場報告亮點

  • 由於患病率不斷增加以及 FDA 為滿足不斷成長的需求而核准的非專利藥數量不斷增加，遠端甲下甲癬細分市場在 2022 年佔據主導地位。
  • 由於易於使用和管理，可提高患者的治療依從性，預計外用藥物領域在預測期內將呈現最快的成長速度。
  • 競爭對手越來越注重購買資本集中專用設備，以維持和發展其競爭優勢。
  • 由於醫療保健條件良好、目標人口廣泛以及治療普及率較高，北美在 2022 年佔據了最大的市場佔有率。

目錄

第1章調查方法與範圍

第2章甲癬市場：執行摘要

  • 市場概述
  • 類型簡介
  • 治療簡介
  • 競爭格局概覽

第 3 章：甲癬市場變數、趨勢與範圍

  • 市場區隔和範圍
  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
  • 市場促進因素分析
    • 甲癬發生率增加
    • 提高對甲癬治療的認知
    • 老年人和糖尿病患者增加
  • 市場限制因素分析
    • 老年人和糖尿病患者增加
  • 指甲癬市場分析工具
    • 產業分析-波特五力分析
    • PESTLE分析
    • 價格分析
    • 管道分析

第4章甲癬市場：按類型估計和趨勢分析

  • 全球甲真菌病市場：按類型細分儀表板
  • 全球甲癬市場：類型變異分析
  • 2018-2030年全球甲癬市場規模及趨勢分析（按類型）
  • 遠端灰指甲
  • 淺層白色灰指甲
  • 近端灰指甲
  • 其他類型

第5章甲癬市場：依治療方法估算與趨勢分析

  • 全球甲癬市場：治療細分儀表板
  • 全球甲癬市場：治療差異分析
  • 2018-2030年全球甲癬市場規模與趨勢分析（依治療方法）
  • 口服
  • 外用
  • 其他

第6章 區域業務分析

  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 西班牙
    • 法國
    • 義大利
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 泰國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 公司/競爭對手分類
  • 參與企業概況
  • 財務表現
  • 產品外用
  • 公司市場佔有率分析
  • 策略規劃，2023 年
    • Bausch Health Companies Inc.
    • GSK plc.
    • Abbott
    • Pfizer, Inc.
    • Bayer AG
    • Teva Pharmaceutical Industries Ltd.
    • Cipla Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Sun Pharmaceutical Industries Ltd.
    • Moberg Pharma AB
Product Code: GVR-4-68040-031-4

Onychomycosis Market Growth & Trends:

The global onychomycosis market size was estimated at USD 4.94 Billion in 2030 and is expected to grow at a CAGR of 4.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of the onychomycosis market is attributable to the increasing incidence of onychomycosis and chronic diseases aided by rising awareness about treatment. The infection leads to psychological and social limitations which can limit an individual's ability to work and socialize which makes it important to provide effective and efficient treatment for patients suffering from the infection further propelling the market growth.

Rising rate of onychomycosis is the key factor contributing to the overall growth of the market. The infection, often known as toenail fungus or fungal nail infection, affects over 14% of the total population in the U.S. However, most people are unaware of how harmful toenail fungus is, despite it is extremely contagious in nature and increasing the risk of developing with age.

International organizations such as the Global Nail Fungus Organization are working with public health officials and healthcare professionals worldwide to increase awareness and improve the prevention and treatment of nail fungus across the globe. This is anticipated to propel the demand for therapeutics. Government initiatives such as Think Fungus by the Centers for Disease Control and Prevention (CDC), emphasize the significance of detecting fungal diseases such as onychomycosis, early enough in the course of a patient's condition to ensure the administration of relevant therapy. This is inducing a surge in demand for onychomycosis therapeutics and is expected to drive market growth in the country.

Furthermore, the key players are focusing on collaborations and partnerships to develop novel onychomycosis therapies and to maintain their competitive position in the market. For instance, in August 2022, Moberg Pharma AB entered into a distribution agreement with Padagis Israel Agencies Ltd. that is expected to give Padagis exclusive rights for selling and marketing MOB-015, a treatment for onychomycosis in Israel. Moreover, innovations to address the concerns such as improving patient compliance and reducing the dosage are expected to fuel the market growth. For instance, in October 2021, Intas Pharmaceuticals launched SB 100mg under the brand name Itaspor-SB Forte/Subawin which is the world's first Super Bioavailable Itraconazole. This initiative is expected to significantly increase patient compliance and reduce the cost of therapy.

Onychomycosis Market Report Highlights:

  • Distal subungual onychomycosis segment dominated the market in 2022 and is attributable to the increasing prevalence and number of generic approvals by the FDA to meet the rising demands
  • Topical segment is expected to show the fastest growth rate over the forecast period owing to ease of usage and administration which leads to increased patient compliance with treatment
  • Players have an increased focus on acquiring specialized capacities that are highly capital-intensive to develop and maintain their competitive position
  • North America held the largest market share in 2022 which can be attributed to better access to healthcare, the presence of a wide target population, and high adoption of treatment

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Type Segment
      • 1.1.1.2. Treatment Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information Or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Primary Sources
  • 1.11. List of Abbreviations

Chapter 2. Onychomycosis Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Type Snapshot
  • 2.3. Treatment Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Onychomycosis Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Increasing Incidence of Onychomycosis
    • 3.4.2. Rising Awareness About Treatment of Onychomycosis
    • 3.4.3. Rising Awareness About Treatment of Onychomycosis
    • 3.4.4. Growing Geriatric and Diabetic Populations
  • 3.5. Market Restraint Analysis
    • 3.5.1. Growing Geriatric and Diabetic Populations
  • 3.6. Onychomycosis Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat of New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Technological Landscape
      • 3.6.2.3. Economic Landscape
    • 3.6.3. Pricing Analysis
    • 3.6.4. Pipeline Analysis

Chapter 4. Onychomycosis Market: Type Estimates & Trend Analysis

  • 4.1. Global Onychomycosis Market: Type Segment Dashboard
  • 4.2. Global Onychomycosis Market: Type Movement Analysis
  • 4.3. Global Onychomycosis Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
  • 4.4. Distal Subungual Onychomycosis
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. White Superficial Onychomycosis
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.6. Proximal Subungual Onychomycosis
    • 4.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.7. Other Types
    • 4.7.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. Onychomycosis Market: Treatment Estimates & Trend Analysis

  • 5.1. Global Onychomycosis Market: Treatment Segment Dashboard
  • 5.2. Global Onychomycosis Market: Treatment Movement Analysis
  • 5.3. Global Onychomycosis Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Oral
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Topical
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. Regional Business Analysis

  • 6.1. Regional Market Dashboard
  • 6.2. Global Regional Market Snapshot
  • 6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.4. North America
    • 6.4.1. U.S.
      • 6.4.1.1. Key Country Dynamics
      • 6.4.1.2. Competitive Scenario
      • 6.4.1.3. Regulatory Framework/Reimbursement Framework
      • 6.4.1.4. U.S. Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Canada
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Competitive Scenario
      • 6.4.2.3. Regulatory Framework/Reimbursement Framework
      • 6.4.2.4. Canada Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. UK
      • 6.5.1.1. Key Country Dynamics
      • 6.5.1.2. Competitive Scenario
      • 6.5.1.3. Regulatory Framework/Reimbursement Framework
      • 6.5.1.4. UK Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Germany
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Competitive Scenario
      • 6.5.2.3. Regulatory Framework/Reimbursement Framework
      • 6.5.2.4. Germany Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Spain
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Competitive Scenario
      • 6.5.3.3. Regulatory Framework/Reimbursement Framework
      • 6.5.3.4. Spain Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Competitive Scenario
      • 6.5.4.3. Regulatory Framework/Reimbursement Framework
      • 6.5.4.4. France Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Competitive Scenario
      • 6.5.5.3. Regulatory Framework/Reimbursement Framework
      • 6.5.5.4. Italy Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.6. Denmark
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Competitive Scenario
      • 6.5.6.3. Regulatory Framework/Reimbursement Framework
      • 6.5.6.4. Denmark Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Sweden
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Competitive Scenario
      • 6.5.7.3. Regulatory Framework/Reimbursement Framework
      • 6.5.7.4. Sweden Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.8. Norway
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Competitive Scenario
      • 6.5.8.3. Regulatory Framework/Reimbursement Framework
      • 6.5.8.4. Norway Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Japan
      • 6.6.1.1. Key Country Dynamics
      • 6.6.1.2. Competitive Scenario
      • 6.6.1.3. Regulatory Framework/Reimbursement Framework
      • 6.6.1.4. Japan Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. China
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Competitive Scenario
      • 6.6.2.3. Regulatory Framework/Reimbursement Framework
      • 6.6.2.4. China Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.3. India
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Competitive Scenario
      • 6.6.3.3. Regulatory Framework/Reimbursement Framework
      • 6.6.3.4. India Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.4. South Korea
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Competitive Scenario
      • 6.6.4.3. Regulatory Framework/Reimbursement Framework
      • 6.6.4.4. South Korea Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Thailand
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Competitive Scenario
      • 6.6.5.3. Regulatory Framework/Reimbursement Framework
      • 6.6.5.4. Thailand Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Competitive Scenario
      • 6.6.6.3. Regulatory Framework/Reimbursement Framework
      • 6.6.6.4. Australia Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Brazil
      • 6.7.1.1. Key Country Dynamics
      • 6.7.1.2. Competitive Scenario
      • 6.7.1.3. Regulatory Framework/Reimbursement Framework
      • 6.7.1.4. Brazil Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. Mexico
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Competitive Scenario
      • 6.7.2.3. Regulatory Framework/Reimbursement Framework
      • 6.7.2.4. Mexico Onychomycosis Market, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Competitive Scenario
      • 6.7.3.3. Regulatory Framework/Reimbursement Framework
      • 6.7.3.4. Argentina Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. South Africa
      • 6.8.1.1. Key Country Dynamics
      • 6.8.1.2. Competitive Scenario
      • 6.8.1.3. Regulatory Framework/Reimbursement Framework
      • 6.8.1.4. South Africa Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Saudi Arabia
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Competitive Scenario
      • 6.8.2.3. Regulatory Framework/Reimbursement Framework
      • 6.8.2.4. Saudi Arabia Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.3. UAE
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Competitive Scenario
      • 6.8.3.3. Regulatory Framework/Reimbursement Framework
      • 6.8.3.4. UAE Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.8.4. Kuwait
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Competitive Scenario
      • 6.8.4.3. Regulatory Framework/Reimbursement Framework
      • 6.8.4.4. Kuwait Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company /Competition Categorization
  • 7.2. Participant Overview
  • 7.3. Financial Performance
  • 7.4. Product Overview
  • 7.5. Company Market Share Analysis
  • 7.6. Strategy Mapping, 2023
    • 7.6.1. Bausch Health Companies Inc.
      • 7.6.1.1. Overview
      • 7.6.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.1.3. Product Benchmarking
      • 7.6.1.4. Strategic Initiatives
    • 7.6.2. GSK plc.
      • 7.6.2.1. Overview
      • 7.6.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.2.3. Product Benchmarking
      • 7.6.2.4. Strategic Initiatives
    • 7.6.3. Abbott
      • 7.6.3.1. Overview
      • 7.6.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.3.3. Product Benchmarking
      • 7.6.3.4. Strategic Initiatives
    • 7.6.4. Pfizer, Inc.
      • 7.6.4.1. Overview
      • 7.6.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.4.3. Product Benchmarking
      • 7.6.4.4. Strategic Initiatives
    • 7.6.5. Bayer AG
      • 7.6.5.1. Overview
      • 7.6.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.5.3. Product Benchmarking
      • 7.6.5.4. Strategic Initiatives
    • 7.6.6. Teva Pharmaceutical Industries Ltd.
      • 7.6.6.1. Overview
      • 7.6.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.6.3. Product Benchmarking
      • 7.6.6.4. Strategic Initiatives
    • 7.6.7. Cipla Inc.
      • 7.6.7.1. Overview
      • 7.6.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.7.3. Product Benchmarking
      • 7.6.7.4. Strategic Initiatives
    • 7.6.8. Merck & Co., Inc.
      • 7.6.8.1. Overview
      • 7.6.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.8.3. Product Benchmarking
      • 7.6.8.4. Strategic Initiatives
    • 7.6.9. Novartis AG
      • 7.6.9.1. Overview
      • 7.6.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.9.3. Product Benchmarking
      • 7.6.9.4. Strategic Initiatives
    • 7.6.10. Sun Pharmaceutical Industries Ltd.
      • 7.6.10.1. Overview
      • 7.6.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.10.3. Product Benchmarking
      • 7.6.10.4. Strategic Initiatives
    • 7.6.11. Moberg Pharma AB
      • 7.6.11.1. Overview
      • 7.6.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
      • 7.6.11.3. Product Benchmarking
      • 7.6.11.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Incidence of Diseases
  • Table 4 Global Onychomycosis Market, By Region, 2018 - 2030 (USD Million)
  • Table 5 North America Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 6 North America Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 7 North America Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 8 U.S. Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 9 U.S. Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 11 Canada Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 12 Europe Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 13 Europe Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 14 Europe Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 15 Germany Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 16 Germany Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 17 UK Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 18 UK Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 19 France Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 20 France Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 21 Italy Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 22 Italy Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 23 Spain Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 24 Spain Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 25 Denmark Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 26 Denmark Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 27 Sweden Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 28 Sweden Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 30 Norway Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 31 Asia Pacific Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Onychomycosis Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Japan Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 35 Japan Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 36 China Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 37 China Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 38 India Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 39 India Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 40 South Korea Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 41 South Korea Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 42 Australia Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 43 Australia Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 44 Thailand Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 45 Thailand Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 46 Latin America Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 47 Latin America Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 48 Latin America Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 49 Brazil Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 50 Brazil Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 51 Mexico Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 52 Mexico Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 53 Argentina Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 54 Argentina Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 55 Middle East & Africa Onychomycosis Market, By Country, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 60 South Africa Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 61 South Africa Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 62 UAE Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 63 UAE Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)
  • Table 64 Kuwait Onychomycosis Market, By Type, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Onychomycosis Market, By Treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Onychomycosis Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 Penetration & Growth Prospect Mapping
  • Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 13 Porter's Five Forces Analysis
  • Fig. 14 Market Penetration & Growth Prospect Mapping
  • Fig. 15 Onychomycosis market: Type outlook and key takeaways
  • Fig. 16 Onychomycosis market: Type movement analysis & market share 2023 & 2030
  • Fig. 17 Distal subungual onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 White superficial onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Proximal subungual onychomycosis market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Onychomycosis market: Treatment outlook and key takeaways
  • Fig. 22 Onychomycosis market: Treatment movement analysis & market share 2023 & 2030
  • Fig. 23 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Regional Marketplace: Key Takeaways
  • Fig. 27 Regional Outlook, 2023 & 2030
  • Fig. 28 Regional Market Dashboard
  • Fig. 29 Regional Market: Key Takeaways
  • Fig. 30 North America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 31 U.S. Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Canada Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Europe Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 34 UK Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Germany Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 36 France Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Italy Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Spain Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Denmark Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Sweden Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Norway Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Asia-Pacific Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Japan Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 44 China Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 45 India Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Thailand Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 48 South Korea Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Latin America Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 50 Brazil Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Mexico Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Argentina Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 53 MEA Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 54 South Africa Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 55 Saudi Arabia Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 56 UAE Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 57 Kuwait Market Estimates and Forecast, 2018 - 2030 (USD Million)
  • Fig. 58 Strategy Mapping